Cognitive & NootropicAlso known as: FPE 1070

Cerebrolysin

Porcine brain-derived peptide mixture approved in 40+ countries for stroke, TBI, and Alzheimer's disease.

Half-Life

~2-4 hours (peptide mix)

Dose Range

5-30 mL/day (IV/IM)

Frequency

1× daily for 10-20 days

Vial Sizes

N/A (oral)

🔬 Mechanism of Action

Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids produced by controlled enzymatic proteolysis of lipid-free porcine brain proteins. It contains neurotrophic factors analogous to BDNF, CNTF, and GDNF.

Cerebrolysin promotes neurogenesis (new neuron formation), synaptogenesis (new synaptic connections), neuronal survival, and recovery from ischemic damage. It is approved in 40+ countries for stroke, traumatic brain injury, Alzheimer's disease, and other neurodegenerative conditions.

Source: PMID: 21281685

📜Background & History

Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins (primarily neocortex), developed in Austria in 1949 by Ernst Ebewe. It contains a mixture of short peptides and free amino acids replicating the neurotrophic factor profile of BDNF, NGF, GDNF, IGF-1, and CNTF. Unlike recombinant growth factors that cannot cross the blood-brain barrier, Cerebrolysin's small peptide fragments do penetrate CNS tissue. It is approved in 41 countries for stroke, TBI, and dementia, with over 100 clinical trials and 40+ years of clinical use history.

🎯 Research Use Cases

✓Acute and chronic stroke rehabilitation (approved in 41 countries)
✓Traumatic brain injury (TBI) recovery
✓Alzheimer's disease and vascular dementia (neuroprotection)
✓Post-COVID cognitive impairment ("brain fog")
✓Performance nootropic: memory, processing speed, neuroplasticity

💉 Dosing Protocol

Typical Dose	5-30 mL/day (IV/IM)
Frequency	1× daily for 10-20 days
Half-Life	~2-4 hours (peptide mix)

⚠️Safety & Considerations

Approved in 40+ countries. Administered IV or IM only — not subcutaneous. Generally well-tolerated. May cause headache, dizziness, or injection site reactions. Contraindicated in severe renal impairment and status epilepticus.

⚡Interactions & Contraindications

Do not mix with 5-HT containing solutions or balanced amino acid infusions. Rare: CNS stimulatory effects — reduce dose if severe sleep disruption occurs. Anti-epileptic drugs: monitor seizure threshold (both Cerebrolysin and some anti-epileptics lower threshold). Anti-MAO drugs: potential interaction with aminergic components.

🔗Synergies & Common Stacks

+ Dihexa

Cerebrolysin provides the neurotrophic factors (BDNF-like activity); Dihexa promotes the synaptogenesis HGF/MET pathway to build the synaptic connections those factors support.

+ Semax

Semax upregulates endogenous BDNF; Cerebrolysin delivers exogenous BDNF-like peptides. Together they comprehensively support neural repair and plasticity from multiple angles.

Cerebrolysin dosing guide infographic showing dose range 5-30 mL/day (IV/IM), half-life ~2-4 hours (peptide mix), and reconstitution example — Cerebrolysin dosing quick reference — 5-30 mL/day (IV/IM), 1× daily for 10-20 days

❓ Frequently Asked Questions

Is Cerebrolysin available in the US?▼

Cerebrolysin is not FDA-approved in the US but is approved in 40+ countries. Some US physicians prescribe it off-label. It is most widely used in Europe, Russia, and Asia for neurological conditions.

How is Cerebrolysin administered?▼

5-30 mL daily via IV infusion or intramuscular injection for 10-20 day courses. IV is preferred for higher doses (>10 mL). It is NOT a subcutaneous injection peptide.

📖 References

Ruther E, et al. “Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized trial.” J Neural Transm (2000). PMID: 10960558

← Back to Peptide Library